This symposium is supported by GSK.
Stephanie Lheureux, MD, PhD, Princess Margaret Cancer Centre, Toronto, Canada
Robert L. Coleman, MD, FACOG, FACS, The University of Texas MD Anderson Cancer Center, Houston, TX
Ana Oaknin, MD, PhD, Vall d´Hebron University Hospital. Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
Rebecca Kristeleit, MD, University College London Hospital, London, UK
Please join our expert Faculty for a 90-minute symposium that will provide an overview of the increasing promise of immunotherapy for the treatment of endometrial cancer. Endometrial cancers comprise over 50% of new gynecologic tumor diagnoses in the United States. The Faculty will review how disease staging has evolved from a purely clinical-based approach to one that incorporates integrated biomarker-based classification. The Faculty will explore the practical use of these biomarkers during the journey of patients with recurrent endometrial cancer. Advances in immunotherapy have revolutionized the treatment of solid tumors but only recently has the potential of these therapies emerged in endometrial cancer. Clinical studies that led to the first approval of an immunotherapy-based regimen for the disease will be discussed along with trials that may further add to the treatment armamentarium.